Anemia Associated with Uterine Fibroids (Pre-surgical)
Estimated Market Size
The National Uterine Fibroids Foundation estimates that as many as 80% of all women in the United States have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment.
- 700,000 women in the seven major market countries have symptoms severe enough to require surgery or radical treatment.
- 40% of the 700,000 (280,000) will have anemia severe enough to pose a surgical risk.
Current Standard of Care
- Hormone therapy
- Oral contraceptives and progestins
- Androgens
- Gonadotropin releasing hormone agonists, (GnRH agonists), for example, Lupron® (leuprolide acetate). Chronic administration of GnRH agonists reduces the number of GnRH receptors and thereby blocks the action of GnRH in stimulating the pituitary to secrete FSH and LH.
- GnRH agonists tend to promote bone loss after six months of use
- Upon cessation of treatment, fibroids typically regenerate rapidly.
- Iron supplementation